Regnante Keith 4

What Happened Keith Regnante, Chief Financial Officer of Keros Therapeutics (KROS), disposed of 4,739 shares on 2026-02-18 in an open-market sale with a weighted-average price of $16.35, generating approximately $77,483. The sale was an automatic "sell-to-cover" to satisfy tax withholding related to vested restricted stock units, not a discretionary market-timing sale.

Key Details

• Transaction date: 2026-02-18 (reported on Form 4 filed 2026-02-20; filing appears timely)
• Shares sold: 4,739; weighted-average price: $16.35; total proceeds ≈ $77,483
• Price range for the multiple trades: $16.05 to $16.65 (per footnote)
• Reason/code: sell-to-cover for tax withholding (automatic; not at insider’s discretion)
• Shares owned after transaction: not disclosed in the provided filing
• Footnote offer: insider will provide full breakdown of number of shares sold at each price upon request

Context Sell-to-cover transactions are common when restricted stock units vest and typically reflect tax-liability management rather than a directional bet on the company. This transaction should be viewed as routine tax-related selling, not necessarily an indicator of the CFO’s view on Keros Therapeutics’ stock.